Is tirzepatide used for diabetes — and what does that mean for weight loss?

How tirzepatide's dual licence came about

Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) which together influence insulin secretion, appetite signalling and the speed at which the stomach empties. That dual mechanism made it a plausible candidate for both blood-sugar control and weight reduction, and Eli Lilly ran separate large clinical programmes to establish each use. The SURPASS trial series established its diabetes credentials; the SURMOUNT programme examined weight management, including in people who had diabetes and those who did not.

The MHRA granted Mounjaro its UK licence for type 2 diabetes first, and the weight-management authorisation followed. In practice this means UK prescribers can reach for the same pen for very different patients. Our Mounjaro overview sets out how the medicine works in more detail.

NICE's appraisal of tirzepatide for weight management, TA1026, applies to adults with a BMI of 35 or above plus at least one weight-related comorbidity, type 2 diabetes qualifies as one of those comorbidities. A separate NICE technology appraisal covers its diabetes use. The two pathways are clinically distinct even when the same person might theoretically qualify for both.

What the trial data shows when diabetes and obesity overlap

SURMOUNT-2 enrolled adults who had both obesity and type 2 diabetes, a population that weight-loss trials sometimes exclude. Over 72 weeks, participants on tirzepatide 15mg lost roughly 15% of their body weight on average, and their HbA1c (the standard blood-sugar marker) fell substantially. Those are meaningful numbers; the weight loss was smaller than in SURMOUNT-1, which enrolled people without diabetes, but still well beyond what older medicines typically achieve. The Lancet published the SURMOUNT-2 results.

For people using tirzepatide primarily for blood-sugar control, weight loss is often a welcome secondary effect rather than the stated goal. The clinical review before prescribing needs to account for both, because falling glucose levels may require a reduction in other diabetes medicines (particularly sulfonylureas or insulin) to avoid hypoglycaemia. That is a conversation for a prescriber with full sight of the patient's current regimen, not something an online consultation resolves without the right clinical background.

If you are already on treatment for diabetes and considering tirzepatide for weight management, our tirzepatide and diabetes page covers the clinical picture in more depth.

Who can and cannot use tirzepatide, the diabetes-specific considerations

For the weight-management licence, adults with type 2 diabetes and a qualifying BMI are eligible provided there are no contraindications. Type 1 diabetes is a different situation entirely: tirzepatide has not been studied in type 1, and management of that condition requires specialist input well beyond what a weight-management service provides. Our tirzepatide and type 1 diabetes page addresses this directly, but the short answer is that anyone with type 1 should speak to their diabetes team rather than approaching a weight-loss service.

People with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, should not use tirzepatide regardless of the indication. A history of pancreatitis requires discussion with a prescriber before starting. Pregnancy, breastfeeding or actively trying to conceive are all situations where tirzepatide is not recommended; the medicine should be stopped before attempting conception, with the timing agreed with a clinician.

The BNF's tirzepatide entry lists the full set of contraindications and cautions for UK prescribers. A named prescriber (a real clinician, not a process) reviews every consultation at nume before any prescription is issued.

Practical things worth knowing if diabetes is part of your picture

If your GP already prescribes tirzepatide for diabetes, starting it separately through a private weight-loss service creates a risk of duplicate prescribing. Tell any online service about existing treatments; at nume, the prescriber checks the clinical picture before approving anything.

Blood-glucose monitoring matters more in the early weeks when doses are increasing. People on insulin or sulfonylureas may find their readings drop faster than expected as tirzepatide takes effect, and their diabetes team should know treatment has started. GP notification is built into our process, it is not optional.

One practical note: if you are thinking about starting in January after the holidays, or timing a first order around payday, it is worth knowing our prescribers work Monday to Friday and orders placed before midday are dispatched the same day once approved. There is no benefit to waiting for a particular week; clinical suitability is the only factor that determines whether a prescription is issued.

If cost is part of your thinking, our Mounjaro price comparison page sets out what a legitimate private prescription includes and how private pricing has shifted since Eli Lilly's UK list-price change in autumn 2025. And if you would like to understand whether Mounjaro is used for diabetes, including which patient groups now have access through primary care, this page on tirzepatide for type 2 diabetes on the NHS covers the phased rollout.